

Taiwan Email Campaign MLR Review Form For Veeva Vault PromoMats and MedComms

- Please fill in Veeva approved email(VAE) and Sales Force Marketing Cloud (SFMC mass email) information of external marketing/medical emails for local review process
- This form needs to be attached to corresponding email for local review process

Product/Therapeutic Area 產品/治療領域	<input type="checkbox"/> Marketing: <input checked="" type="checkbox"/> Medical:
Subject 郵件主旨 (VAE& Mass email)	突破乳癌照護困境 專家跨科 Talk Show
Pre-header 郵件預覽內容 (Mass email only)	跨科專家解析照護心法，強化診間決策不卡關

2026



Hybrid meeting

F2F & virtual

Breast Cancer x Experts : Live On Stage

Leveraging real-world insights to improve
treatment quality and policy alignment.



SCAN the QRcode

REGISTER NOW

4/17 / FRIDAY

19:00~20:30

台北喜來登 B1 玉瀾+薈萃廳

Meeting Objectives

- 突破處置副作用瓶頸，讓治療走得更遠：衛教 × 監測 × 臨床妙解
- Pay for Performance 乳癌照護落地診間：掌握政策 × 優化臨床實務應用



• 高醫附醫
陳芳銘 教授



• 林口長庚
郭玟伶 醫師



• 台大醫院
黃柏翔 醫師



• 三軍總醫院
馮安捷 醫師

Time

Session

Speaker

Moderator

19:00-19:05 Welcome and Opening Remarks 陳芳銘 教授 高醫附醫

19:05-19:35 當標準處置不足時：如何突破腹瀉與疲憊的處理困境 (30 mins)

19:35-20:05 從健保新政策到診間：Pay for Performance 下的臨床思考? (30 mins)

郭玟伶 醫師 林口長庚
黃柏翔 醫師 台大醫院
馮安捷 醫師 三軍總醫院

陳芳銘 教授
高醫附醫

20:05-20:25 臨床決策思維於臨床實務之應用 Q&A：專家解析 (20 mins)

20:25-20:30 Summary and Wrap-Up

陳芳銘 教授 高醫附醫

This event is strictly by invitation only. Attendance is limited to individuals who have received an official invitation. Please note that uninvited guests, including immediate family members and friends, are not permitted to attend. We appreciate your understanding and cooperation in maintaining the exclusivity and confidentiality of this meeting.

CONFIDENTIALITY AND NO FURTHER DISTRIBUTION NOTICE:

This communication is intended solely for Healthcare Professionals (HCPs) who are registered to receive information from Eli Lilly and Company ("Lilly"). If you are not an HCP in Taiwan, please delete and destroy any copies of this email immediately, as it was sent to you in error.

The information contained herein is provided exclusively as medical communication in response to your scientific information needs. It is not intended to promote any product. Accordingly, it should not be further distributed.

For complete prescribing information, please refer to the current product label available at: <https://mcp.fda.gov.tw/im>. Please note that certain web links included in this email may direct you to third-party websites. They are independent from Lilly and Lilly has no control over, or responsibility for, their information or accuracy.

This email, including all attachments and embedded links, is intended solely for the use of the designated recipient and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution of this communication is strictly prohibited.

If you are not the intended recipient, please notify the sender by replying to this email and delete all copies of the original message.

If you are not the intended recipient, please contact the sender by reply email and destroy copies of the original message.

We respect your right to privacy - [Privacy statement](#) | [Unsubscribe](#)

This email was sent by: Eli Lilly and Company, Medical Team
14F., No. 9 & 11 Songgao Road Xinyi District Taipei City 110 Taiwan